Truist Securities Maintains Hold on Apogee Therapeutics, Raises Price Target to $135

Benzinga · 3d ago
Truist Securities analyst Danielle Brill maintains Apogee Therapeutics (NASDAQ:APGE) with a Hold and raises the price target from $81 to $135.